These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26761396)

  • 21. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporation of Ebola glycoprotein into HIV particles facilitates dendritic cell and macrophage targeting and enhances HIV-specific immune responses.
    Ao Z; Wang L; Mendoza EJ; Cheng K; Zhu W; Cohen EA; Fowke K; Qiu X; Kobinger G; Yao X
    PLoS One; 2019; 14(5):e0216949. PubMed ID: 31100082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms.
    Murji AA; Qin JS; Hermanus T; Morris L; Georgiev IS
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
    Buonaguro L; Devito C; Tornesello ML; Schröder U; Wahren B; Hinkula J; Buonaguro FM
    Vaccine; 2007 Aug; 25(32):5968-77. PubMed ID: 17629365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant.
    Vassilieva EV; Wang BZ; Vzorov AN; Wang L; Wang YC; Bozja J; Xu R; Compans RW
    mBio; 2011; 2(1):e00328-10. PubMed ID: 21325038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
    Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
    J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms.
    Donnelly L; Curran RM; Tregoning JS; McKay PF; Cole T; Morrow RJ; Kett VL; Andrews GP; Woolfson AD; Malcolm RK; Shattock RJ
    Vaccine; 2011 Jun; 29(27):4512-20. PubMed ID: 21514349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
    Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
    Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP; Young KR; Ross TM
    Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.
    Melo M; Porter E; Zhang Y; Silva M; Li N; Dobosh B; Liguori A; Skog P; Landais E; Menis S; Sok D; Nemazee D; Schief WR; Weiss R; Irvine DJ
    Mol Ther; 2019 Dec; 27(12):2080-2090. PubMed ID: 31515132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deglycosylation of HIV-1 AE Gp140 enhances the capacity to elicit neutralizing antibodies against the heterologous HIV-1 clade.
    Zhang C; Wan Y; Shi J; Zhou M; Meng Z; Yuan S; Qiu C; Zhang X; Xu X; Liu C; Xu J
    AIDS Res Hum Retroviruses; 2010 May; 26(5):569-75. PubMed ID: 20455767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Particle-based delivery of the HIV envelope protein.
    Asbach B; Wagner R
    Curr Opin HIV AIDS; 2017 May; 12(3):265-271. PubMed ID: 28422790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.
    Weaver EA; Camacho ZT; Gao F
    AIDS Res Hum Retroviruses; 2010 May; 26(5):577-84. PubMed ID: 20438382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.
    Sharma VA; Kan E; Sun Y; Lian Y; Cisto J; Frasca V; Hilt S; Stamatatos L; Donnelly JJ; Ulmer JB; Barnett SW; Srivastava IK
    Virology; 2006 Aug; 352(1):131-44. PubMed ID: 21894641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.
    Bricault CA; Kovacs JM; Nkolola JP; Yusim K; Giorgi EE; Shields JL; Perry J; Lavine CL; Cheung A; Ellingson-Strouss K; Rademeyer C; Gray GE; Williamson C; Stamatatos L; Seaman MS; Korber BT; Chen B; Barouch DH
    J Virol; 2015 Mar; 89(5):2507-19. PubMed ID: 25540368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Components of a HIV-1 vaccine mediate virus-like particle (VLP)-formation and display of envelope proteins exposing broadly neutralizing epitopes.
    Rosengarten JF; Schatz S; Wolf T; Barbe S; Stitz J
    Virology; 2022 Mar; 568():41-48. PubMed ID: 35101772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.